AU3172397A - Anti-neurodegeneratively effective xanthene derivatives - Google Patents

Anti-neurodegeneratively effective xanthene derivatives

Info

Publication number
AU3172397A
AU3172397A AU31723/97A AU3172397A AU3172397A AU 3172397 A AU3172397 A AU 3172397A AU 31723/97 A AU31723/97 A AU 31723/97A AU 3172397 A AU3172397 A AU 3172397A AU 3172397 A AU3172397 A AU 3172397A
Authority
AU
Australia
Prior art keywords
neurodegeneratively
effective
xanthene derivatives
xanthene
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU31723/97A
Inventor
Claudia Betschart
Silvio Roggo
Kaspar Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG, Novartis AG filed Critical Ciba Geigy AG
Publication of AU3172397A publication Critical patent/AU3172397A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/90—Xanthenes with hydrocarbon radicals, substituted by amino radicals, directly attached in position 9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU31723/97A 1996-06-05 1997-06-04 Anti-neurodegeneratively effective xanthene derivatives Abandoned AU3172397A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CH1431/96 1996-06-05
CH143196 1996-06-05
CH180496 1996-07-18
CH1804/96 1996-07-18
PCT/EP1997/002885 WO1997046549A1 (en) 1996-06-05 1997-06-04 Anti-neurodegeneratively effective xanthene derivatives

Publications (1)

Publication Number Publication Date
AU3172397A true AU3172397A (en) 1998-01-05

Family

ID=25687631

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31723/97A Abandoned AU3172397A (en) 1996-06-05 1997-06-04 Anti-neurodegeneratively effective xanthene derivatives

Country Status (2)

Country Link
AU (1) AU3172397A (en)
WO (1) WO1997046549A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19947521A1 (en) 1999-10-02 2001-04-05 Basf Coatings Ag Solid mixture for use in coating, adhesive or sealant materials, e.g. for painting cars, contains a solid acrylic copolymer and another solid compound, both with groups containing UV-polymerizable bonds
DE10126651A1 (en) 2001-06-01 2002-12-12 Basf Coatings Ag Use of copolymers with diphenylethylene units as emulsifiers for the production of powder slurry and coating powder for use in coating materials, adhesives and sealants, e.g. for painting cars
DE10130972C1 (en) 2001-06-27 2002-11-07 Basf Coatings Ag Production of hard, scratch-resistant coatings, e.g. on automobile bodywork, using lacquer containing (meth)acrylate copolymer and photoinitiator, hardened by heat and irradiation in oxygen-depleted atmosphere
DE10353638A1 (en) 2003-11-17 2005-06-23 Basf Coatings Ag Pseudoplastic, aqueous dispersions, process for their preparation and their use
DE102008054283A1 (en) 2008-11-03 2010-06-02 Basf Coatings Japan Ltd., Yokohama Color and / or effect multi-layer coatings with pigment-free coatings as filler replacement, their preparation and use
DE102014007805A1 (en) 2014-05-27 2015-12-03 WindplusSonne GmbH Solar absorber, process for its preparation and its use
US11084807B2 (en) 2016-08-18 2021-08-10 Vidac Pharama Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
WO2018236745A1 (en) 2017-06-20 2018-12-27 Carnot, Llc Compositions and methods for increasing efficiency of cardiac metabolism
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2676971A (en) * 1951-04-21 1954-04-27 Searle & Co Quaternary ammonium derivatives of aminoalkylxanthenes and aminoalkylthiaxanthenes
US2661351A (en) * 1951-07-24 1953-12-01 Searle & Co N-alkyl-9-xanthene-carboxamides, basically substituted derivatives and salts thereof
US2661353A (en) * 1951-08-02 1953-12-01 Searle & Co N, n-disubstituted 9-xanthenecarboxamides
US2956060A (en) * 1953-01-07 1960-10-11 Wander Ag Dr A Xanthene derivatives and process of making same
NL299449A (en) * 1962-10-19
DE2629752A1 (en) * 1976-07-02 1978-01-05 Boehringer Mannheim Gmbh NEW CARBONIC ACID DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION
FR2361883A2 (en) * 1976-04-09 1978-03-17 Fabre Sa Pierre AMIDES OF PYRROLIDINO ETHYL AMINE USED IN PULMONARY THERAPEUTICS
US4868210A (en) * 1988-03-30 1989-09-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
EP0636619A1 (en) * 1991-09-13 1995-02-01 Sankyo Company Limited Tricyclic heterocyclic compound
DE4215213A1 (en) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
AU672699B2 (en) * 1993-06-30 1996-10-10 Sankyo Company Limited Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
PT726265E (en) * 1995-02-08 2001-12-28 Novartis Ag 10-AMINO-ALIFATIL-DIBENZOB, F | OXYPINS WITH ANTINEURODEGENERATIVE ACTION

Also Published As

Publication number Publication date
WO1997046549A1 (en) 1997-12-11

Similar Documents

Publication Publication Date Title
AU1151099A (en) Azaoxindole derivatives
AU1825899A (en) Dota-biotin derivatives
AU2070795A (en) 3-aryl-4-hydroxy-delta3-dihydrothiophenone derivatives
AU7935398A (en) Diaminorhodamine derivatives
AU6117998A (en) 3-oxadiazolylquinoxaline derivatives
AU1735497A (en) Sulfonylureidopyrazole derivatives
AU1594697A (en) New substituted 19-nor-pregnane derivatives
AU3867997A (en) Chromene-3-carboxylate derivatives
AU7738098A (en) Novel tetrahydrobenzindolone derivatives
AU2956097A (en) Alkylaminobenzothiazole and -benzoxazole derivatives
EP1008579A3 (en) Cyclopentenebutanol derivatives
AU2485595A (en) 1-Pyridyltetrazolinone derivatives
AU2961097A (en) Substituted pyrazolylpyrazole derivatives
AU7813598A (en) Betulinol derivatives
AU3172397A (en) Anti-neurodegeneratively effective xanthene derivatives
AU4962097A (en) 2-methoxyphenylpiperazine derivatives
AU1793197A (en) Pyrazole-4-yl-hetaroyl derivatives
AU5347496A (en) Ethynylthiazole derivative
AU1174199A (en) Biphenylamidine derivatives
AU6729498A (en) Thiazolimine derivatives
AU4117396A (en) Morpholinoethylamide derivatives
AU3685097A (en) N-benzylazolium derivatives
AU689566B2 (en) DC-89 derivatives
AU4967797A (en) Benzofuran derivatives
AU3619695A (en) Thioquinolone derivative